Shoreline Biosciences Inc.

Plus: agreements between Rigel-Blueprint, BeiGene-Shoreline and AstraZeneca-FibroGen

Biotechs are developing over 20 types of iPSC-based cell therapies

Fate’s pipeline reprioritization raises questions about iPSC-derived NK cells

Plus: Mathias to become CEO at Oxford, and updates from Novartis and Shoreline

Plus: Shoreline buying Editas NK assets and updates from Intercept, Roche, Seagen and more

Plus Sutro’s CMO leaves and updates from Shoreline, Opthea and Aurinia

Presentations highlight gene edits and CAR engineering to improve efficacy of NK cell therapies

BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference

Syncona’s first allogeneic cell therapy investment goes to Clade, led by Sana and CRISPR Therapeutics co-founder Cowan

The biotechs are turning iPS cells into NK, T, B cells and macrophages